Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Clinical trial NCT05052801 · COMPLETED

Trial details

NCT number: NCT05052801
Sponsor: Amgen
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Gastric Cancer Gastroesophageal Junction Adenocarcinoma

Start date: 2022-03-07
Primary completion: 2025-06-20
Enrollment: 547

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.